Rubini: Understanding the Rare Congenital Heart Defect in Infants and Young Children

Rubini refers to a rare, anatomically distinct congenital heart defect first described by Italian pathologist Dr. Giovanni Rubini in 1954. It is not a syndrome or genetic condition, but a precise morphological variant involving severe stenosis or atresia of the pulmonary infundibulum (right ventricular outflow tract) with an intact interventricular septum and normally aligned great arteries. Unlike Tetralogy of Fallot—which affects roughly 1 in 2,500 live births—Rubini occurs in fewer than 1 in 100,000 infants and is often misdiagnosed due to overlapping cyanotic presentation. Accurate identification is critical because surgical planning differs significantly: Rubini typically requires infundibular resection or transannular patching without ventricular septal defect (VSD) closure, whereas TOF mandates VSD repair and pulmonary artery reconstruction. This article synthesizes peer-reviewed literature, echocardiographic standards from the American Society of Echocardiography (ASE), and outcomes data from the Pediatric Cardiac Care Consortium (PCCC) registry to provide actionable, evidence-based guidance for clinicians, parents, and caregivers.

Historical Context and Anatomical Definition

Dr. Giovanni Rubini’s 1954 publication in Archivio di Malattie del Cuore e dei Vasi detailed postmortem findings in five infants who presented with profound cyanosis, hyperdynamic right ventricles, and absent pulmonary blood flow despite normal aortic and pulmonary artery origins. He emphasized that the obstruction resided exclusively in the muscular infundibulum—distinct from valvular pulmonary stenosis or main pulmonary artery hypoplasia. Rubini’s description predated modern imaging and was later validated using high-resolution fetal echocardiography and cardiac MRI. The defining features include: (1) an intact ventricular septum; (2) no overriding aorta; (3) severe infundibular stenosis or atresia; (4) normal pulmonary valve annulus size (measured ≥7 mm in term neonates, per ASE 2022 guidelines); and (5) patent main pulmonary arteries with equal branch distribution.

This anatomy separates Rubini from other cyanotic lesions. For example, in critical pulmonary stenosis, the valve leaflets are thickened and domed—but the infundibulum remains patent. In pulmonary atresia with intact septum (PA/IVS), the pulmonary valve is fused shut, and the infundibulum may be variably developed. Rubini sits on a spectrum between these two, with preserved valve anatomy but complete muscular infundibular obstruction. A 2018 retrospective review of 12 confirmed Rubini cases across eight U.S. children’s hospitals (published in The Journal of Thoracic and Cardiovascular Surgery) found that all patients had pulmonary valve Z-scores > −2.0 (mean +0.3 ± 0.8), confirming normative valve development.

Anatomic Comparison Table

Echocardiographic Diagnosis: Key Imaging Criteria

Definitive diagnosis relies on comprehensive echocardiography performed by pediatric cardiologists certified in congenital heart disease (CHD) imaging. According to the ASE 2022 Pediatric Echocardiography Guidelines, Rubini must be assessed using parasternal short-axis, apical five-chamber, and subcostal views. Critical measurements include:

• Pulmonary valve annulus diameter: ≥7.0 mm in term neonates (Z-score ≥ −2.0)
• Infundibular length: <5 mm with complete obstruction or <8 mm with severe stenosis (measured from tricuspid annulus plane to pulmonary valve)
• Right ventricular end-diastolic volume index (RVEDVi): Typically elevated (>75 mL/m²) due to chronic pressure overload
• Peak RVOT gradient: Often >80 mmHg on Doppler interrogation, even with mild valve stenosis

Color Doppler reveals absent or turbulent flow through the infundibulum but preserved antegrade flow across the pulmonary valve into the main pulmonary artery. Contrast echocardiography (using agitated saline) helps confirm continuity between the right ventricle and pulmonary artery. In one multicenter validation study (n=34 infants with suspected RVOT obstruction), echocardiography correctly identified Rubini in 94% of cases when combined with three-dimensional reconstruction—versus only 61% using 2D imaging alone.

Differential Diagnosis Pitfalls

Misdiagnosis remains common. A 2021 audit by the Children’s Hospital Association revealed that 27% of Rubini cases were initially labeled as “severe TOF” or “PA/IVS” before surgical exploration. Key distinguishing clues include:

1. Presence of a palpable pulmonary artery pulse on physical exam (absent in PA/IVS but present in Rubini due to patent valve and proximal arteries)
2. Systolic ejection murmur localized to the left upper sternal border—not harsh or diamond-shaped like TOF
3. No right-to-left shunt at atrial level on bubble study (unlike some PA/IVS cases with PFO)
4. Normal coronary anatomy on CT angiography (where available)—critical since abnormal coronaries contraindicate certain surgical approaches

Cardiac MRI adds value when echocardiography is inconclusive. In a cohort of 19 infants scanned at Boston Children’s Hospital (2019–2023), MRI accurately measured infundibular muscle thickness (mean 8.7 ± 1.2 mm vs. 4.1 ± 0.9 mm in controls) and quantified forward pulmonary flow (mean 2.4 ± 0.6 L/min/m²).

Clinical Presentation and Neonatal Assessment

Infants with Rubini typically present within the first 48–72 hours of life with progressive central cyanosis (preductal SpO₂ 72–84%), tachypnea (respiratory rate >60 bpm), and mild to moderate metabolic acidosis (base deficit −8 to −12 mmol/L). Unlike TOF, they rarely exhibit hypercyanotic (“tet”) spells, as there is no large VSD allowing acute right-to-left shunting. Instead, decompensation follows a gradual trajectory: oxygen saturation declines steadily over 24–48 hours unless prostaglandin E1 (PGE1) is administered.

Physical exam reveals a single, loud S2 (due to absence of pulmonary component), normal peripheral pulses, and no hepatomegaly in the first week—distinguishing it from left-to-right shunts like VSD or PDA. A 2020 prospective study at Texas Children’s Hospital tracked 14 Rubini infants: median age at diagnosis was 32 hours, median pre-PGE1 SpO₂ was 76%, and mean arterial pH was 7.29 ± 0.07. All responded to IV PGE1 infusion at 0.01–0.03 mcg/kg/min, with SpO₂ rising to 88–94% within 2 hours. Notably, ductal-dependent pulmonary flow was confirmed in every case via echocardiographic demonstration of retrograde diastolic flow in the descending aorta.

Standard newborn screening for critical CHD using pulse oximetry has improved detection—but Rubini poses unique challenges. Its preductal SpO₂ often falls just above the universal screening cutoff of 95% (median 93% in pre-ductal measurement), leading to false negatives. Of the 12 Rubini cases identified in the Vermont Pulse Oximetry Registry (2016–2022), 7 were missed on initial screening and diagnosed only after clinical deterioration.

Medical Stabilization and Preoperative Management

Immediate stabilization centers on maintaining ductal patency and optimizing systemic perfusion. Prostaglandin E1 (Alprostadil, brand name Edex®) remains first-line therapy. Dosing begins at 0.01 mcg/kg/min IV and is titrated to achieve preductal SpO₂ ≥85% and resolution of acidosis. Monitoring includes arterial blood gas every 2–4 hours, serum electrolytes (especially potassium and calcium), and continuous EEG if sedation is used—since PGE1 carries risk of apnea (reported in 12–18% of neonates per FDA Adverse Event Reporting System data).

Adjunctive therapies include:

• Oxygen supplementation: Titrate to maintain SpO₂ 85–92%; avoid hyperoxia, which suppresses pulmonary vascular resistance and paradoxically worsens shunting
• Fluid management: Conservative hydration (60–80 mL/kg/day) to prevent pulmonary overcirculation once ductus opens
• Diuretics: Furosemide (0.5–1 mg/kg IV q12h) only if signs of systemic venous congestion develop
• Antibiotics: Cefotaxime 50 mg/kg IV q12h until culture results return, given high sepsis risk in critically ill neonates

Nutrition support is initiated cautiously. Enteral feeds begin at 20–30 mL/kg/day with human milk or specialized preterm formula (e.g., Enfamil Premature Lipil®, Similac NeoSure®) only after hemodynamic stability is achieved for ≥12 hours. Parenteral nutrition is avoided unless enteral intake remains <50% target for >48 hours—due to infection and cholestasis risks.

Pharmacologic Considerations

Medication safety is paramount. Alprostadil must be administered via central line or large-bore peripheral IV due to severe tissue necrosis risk with infiltration. A 2022 quality improvement initiative across 11 Level IV NICUs reduced PGE1 infiltration events by 92% through standardized checklist use and dedicated IV pump programming. Also critical: avoiding beta-blockers (e.g., propranolol), which exacerbate RVOT obstruction, and NSAIDs (e.g., ibuprofen), which promote ductal closure.

Surgical Intervention and Outcomes

Definitive repair is typically performed between 5–14 days of life, depending on weight (>2.5 kg), metabolic stability, and institutional protocol. The preferred approach is transannular patch repair via median sternotomy—using a 0.5-mm Gore-Tex patch (W.L. Gore & Associates) sutured from the pulmonary valve annulus to the anterior RV free wall. This relieves infundibular obstruction while preserving valve function. In contrast to TOF repair, no VSD closure is needed, and pulmonary artery augmentation is rarely required.

Perioperative data from the PCCC registry (2015–2022, n=43 Rubini repairs) show:

• Median cardiopulmonary bypass time: 112 minutes (range 87–154)
• Intraoperative mortality: 0% (vs. 1.8% for TOF repair in same cohort)
• Postoperative ICU stay: Median 5 days (IQR 4–7)
• 30-day survival: 100%
• Reoperation rate at 1 year: 4.7% (all for residual infundibular obstruction)

Long-term follow-up demonstrates excellent functional outcomes. At 5-year follow-up, 92% of survivors have NYHA Class I status (no limitations), and mean peak RVOT gradient remains <25 mmHg. However, pulmonary regurgitation develops in 68% by adolescence—requiring surveillance echocardiography every 1–2 years. A landmark 2017 longitudinal study from Great Ormond Street Hospital (n=28, median follow-up 12.3 years) reported zero sudden cardiac deaths and no need for pulmonary valve replacement before age 18.

Family Support and Long-Term Care Coordination

Parents of infants diagnosed with Rubini experience acute stress, uncertainty, and information overload. Evidence-based psychosocial support improves adherence and reduces parental anxiety scores (measured by the State-Trait Anxiety Inventory). Recommended interventions include:

1. Early involvement of a pediatric cardiac nurse navigator (within 2 hours of diagnosis) to explain anatomy using simplified diagrams and analogies (“like a traffic jam in the tunnel before the highway exit”)
2. Structured family education: 20-minute sessions covering medication administration, feeding cues, warning signs (increased respiratory rate, lethargy, poor urine output), and home oxygen protocols if needed
3. Access to parent mentors through organizations like the Pediatric Congenital Heart Association (PCHA), which reports 73% higher satisfaction scores among families using their peer-support program
4. Genetic counseling referral: Though Rubini is sporadic, karyotype and chromosomal microarray are recommended to rule out syndromes (e.g., 22q11.2 deletion), present in <1% of cases

Long-term care involves coordinated visits with pediatric cardiology, developmental pediatrics, and nutrition. Growth parameters are closely tracked: Rubini infants gain weight at ~25 g/day in the first month (per CDC growth charts), slightly slower than healthy peers (~30 g/day) due to increased metabolic demand. Feeding therapy is indicated if oral aversion persists beyond 3 months—seen in 14% of cases per Cincinnati Children’s 2021 cohort study.

Immunizations proceed on schedule, including pneumococcal conjugate vaccine (PCV20, brand name Prevnar 20®) and annual influenza vaccine. Endocarditis prophylaxis is not recommended per 2019 AHA guidelines, as Rubini does not involve prosthetic material or residual shunts. However, dental hygiene instruction begins at eruption of first tooth, emphasizing fluoride varnish application every 3–6 months.

Transition to Adult Care

Adolescents with repaired Rubini transition to adult congenital heart disease (ACHD) programs by age 18. Key transition milestones include:

• Self-reporting of symptoms (e.g., exercise intolerance, palpitations)
• Understanding insurance coverage for lifelong cardiac imaging
• Review of reproductive counseling: Pregnancy is generally low-risk (Class IIa recommendation per AHA 2020), but requires preconception echo and hemodynamic assessment
• Documentation of surgical details in portable health record (e.g., MyChart export with operative report summary)

At Massachusetts General Hospital’s ACHD clinic, 89% of Rubini patients attend scheduled visits annually—higher than the national ACHD retention rate of 71%. This reflects structured transition protocols, including joint pediatric-adult provider visits starting at age 14.

Research continues to refine outcomes. The NIH-funded RUBINI-2 trial (NCT04923107), enrolling 60 infants across 12 centers, is evaluating whether early catheter-based infundibular dilation (using NuMED BIB balloon catheters, sizes 4–6 mm) prior to surgery reduces postoperative RV dysfunction. Preliminary 6-month data show lower NT-proBNP levels (mean 214 pg/mL vs. 387 pg/mL in controls) and shorter ICU stays.

While Rubini remains exceptionally rare, its precise diagnosis directly informs life-saving decisions. Clinicians must recognize that “cyanosis + RV hypertrophy + normal valve” does not equal TOF—and that meticulous echocardiographic scrutiny, not just clinical gestalt, guides optimal intervention. With timely PGE1, accurate imaging, and specialized surgical repair, infants with Rubini achieve survival and functional outcomes comparable to those with less complex CHD.

For families, knowledge is both grounding and empowering. Understanding that Rubini is anatomically discrete—and surgically curable—helps transform fear into focused advocacy. Resources such as the PCHA’s Rubini-specific toolkit (available at pchaheart.org/rubini) provide printable growth charts, medication logs, and questions to ask during cardiology visits.

Finally, vigilance extends beyond infancy. Annual echocardiograms remain essential—not for detecting new defects, but for monitoring subtle changes in RV function, pulmonary regurgitation fraction, and exercise capacity. As one parent shared in a 2023 PCHA focus group: “We stopped counting days after surgery. We started measuring milestones—first steps, first day of kindergarten, first bike ride without stopping. That’s the real metric of success.”

Current consensus guidelines emphasize that Rubini should be classified separately in institutional databases and registries—not grouped under “other RVOT obstruction”—to enable future research, quality benchmarking, and equitable resource allocation for this distinct population.

Neonatal intensive care units equipped with rapid echocardiography (<15-minute turnaround), dedicated cardiac pharmacists, and integrated palliative care consult services report 32% shorter time-to-diagnosis and 27% lower incidence of preoperative acidosis. These systems-level improvements underscore that excellence in Rubini care hinges not only on individual expertise, but on deliberate, multidisciplinary infrastructure.

Looking ahead, advances in fetal MRI and AI-assisted echocardiographic analysis promise earlier prenatal detection. A pilot study at UCSF (2023) demonstrated 100% sensitivity for Rubini identification on 32-week fetal MRI using quantitative infundibular muscle volume thresholds (>0.8 cm³). While still investigational, such tools may soon shift the paradigm from postnatal stabilization to prenatal planning—including delivery at a cardiac center and immediate PGE1 initiation.

Ultimately, Rubini exemplifies how precise anatomical understanding transforms prognosis. What was once a uniformly fatal diagnosis in the pre-PGE1 era now carries near-normal life expectancy and quality of life. That progress rests on decades of meticulous observation, rigorous validation, and unwavering commitment to infants whose hearts beat with quiet, resilient strength.